K90-114TAT
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas.
For research use only. We do not sell to patients.
- Formula: C205H357N77O55
- Molecular Weight:4780.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
Molecular Weight 4780.51
-
Formula C205H357N77O55
-
Sequence
Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln-Gly-Ser-Gly-Ser-Gly-Ser-Tyr-Ala-Ala-Gly-Lys-Ala-Glu-Val-Val-Leu-Gly-Asn-Ile-Ile-Lys-Lys-Lys-Gly-Trp-Arg-Arg-Ser-Ser-Leu-Val
-
Sequence Shortening
GRKKRRQRRRPQGSGSGSYAAGKAEVVLGNIIKKKGWRRSSLV
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
K90-114TAT Related Classifications
HY-P10255 Related Classifications
Powered by Bioz